Azienda Ospedaliera Sant Anna E San Sebastiano Di Caserta
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Azienda Ospedaliera Sant Anna E San Sebastiano Di Caserta, the main focus is cardiovascular research, with trials studying acute myocardial infarction, atrial fibrillation, atherosclerosis, and broader cardiovascular disease. These studies are designed to assess whether new approaches can better prevent major heart and blood vessel events, improve stroke prevention, and reduce future complications in people at high risk.
- Testing new treatments to lower the risk of major adverse cardiovascular events
- Evaluating therapies for stroke and systemic embolism prevention in atrial fibrillation
- Studying options for people recovering from or at risk of acute myocardial infarction
Much of the work in this area also explores primary prevention and risk reduction in patients with elevated cardiovascular risk, including those with elevated lipoprotein(a).
Nutritional and Metabolic Diseases
The site is also active in nutritional and metabolic research, especially studies on hypertriglyceridemia and related atherosclerotic cardiovascular disease. These trials aim to understand whether targeted therapies can improve lipid levels and help lower long-term cardiovascular risk.
- Assessing treatments for high triglycerides
- Exploring ways to reduce cardiovascular risk linked to abnormal lipid profiles
- Supporting prevention strategies for patients with metabolic risk factors
This research reflects a strong interest in connecting metabolic health with heart disease prevention.
Musculoskeletal Diseases
Clinical trials in musculoskeletal disease at this hospital include research on moderate to severe rotator cuff tendinopathy. The goal is to evaluate whether new treatment options can improve shoulder pain, function, and day-to-day mobility for people affected by chronic tendon injury.
- Improving shoulder symptoms and physical function
- Testing therapies for persistent tendon-related pain
- Studying better care options for upper limb mobility problems
Although smaller in scope than the cardiovascular portfolio, this work broadens the site’s clinical research profile beyond heart disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 75 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 73 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
- 1Novartis Pharma AG3active
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG7trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera Sant Anna E San Sebastiano Di Caserta
lock Showing 1 of 43 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 75 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ribociclib | 4 | Unknown | 2024-01-25 | 2025-12-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.